3 withdrawn, 2 completed, 2 recruiting, 1 active not recruiting. 10 Phase 1, 6 Phase 2.
Follow Immunocore Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of IMC-S118AI in Type 1 Diabetes IMC-S118AI - Type 1 Diabetes, Type 1 Diabetes (T1D) | Phase 1 | Not yet recruiting | Immunocore Ltd | 154 | 2026-04-01 | 2026-03-25 |
| Study of IMC-P115C in Advanced PRAME-Positive Cancers IMC-P115C - PRAME Positive, Cancer | Phase 1 | Recruiting | Immunocore Ltd | 140 | 2024-11-07 | 2026-02-25 |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers IMC-R117C, Chemotherapy drug, Kinase inhibitor - Cancer, HLA-A*02:01-positive | Phase 1 / Phase 2 | Recruiting | Immunocore Ltd | 600 | 2024-01-10 | 2026-01-28 |
| Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD - Hepatitis B, Chronic | Phase 1 | Withdrawn | Immunocore Ltd | 2020-08-12 | 2024-10-15 | |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Immunocore Ltd | 410 | 2020-02-25 | 2026-03-06 |
| Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab IMC-C103C, Atezolizumab - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Immunocore Ltd | 2019-05-17 | 2024-10-18 | |
| Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers IMCnyeso - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Immunocore Ltd | 29 | 2018-06-15 | 2022-03-11 |
| A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma IMCgp100 - Uveal Melanoma | Phase 1 / Phase 2 | Completed | Immunocore Ltd | 146 | 2016-02-29 | 2023-03-21 |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma Tebentafusp (IMCgp100) - Malignant Melanoma | Phase 1 / Phase 2 | Withdrawn | Immunocore Ltd | 2015-11-01 | 2024-07-24 | |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma IMCgp100 - Malignant Melanoma | Phase 1 | Completed | Immunocore Ltd | 84 | 2010-09-28 | 2020-07-08 |
Melanoma (3) · Neoplasms (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diabetes Mellitus, Type 1 (1) · Hepatitis B, Chronic (1) · Uveal Melanoma (1)
tebentafusp (3) · Antibodies, Monoclonal (2) · Angiogenesis Inhibitors (1) · Bevacizumab (1) · Drug Therapy (1) · atezolizumab (1) · mycophenolic adenine dinucleotide (1) · pembrolizumab (1)
United States (7) · Spain (6) · United Kingdom (6) · Australia (4) · Canada (3) · Germany (3) · Italy (3) · Belgium (2) · France (2) · Netherlands (2) · South Korea (2) · Austria (1) · Brazil (1) · Denmark (1) · Hong Kong (1)
PMID 36229663, PMID 37286303, PMID 40054461, PMID 42476725
2023 (2), 2019 (1)